Anti-programmed cell death-1 (anti-PD-1) monoclonal antibodies are immune checkpoint inhibitors (ICIs) recently introduced to treat recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) [3,4]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.